Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 25;15(1):130–140. doi: 10.1111/cts.13127

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Genentech Inc/Roche. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

ADA assessment framework for oncology biologics. Immunogenicity assessment in oncology should consider the complex relationship of drug concentrations, ADA/NAb, efficacy, and patient characteristics and prognostic factors. The direction of the arrows indicates the direction of the impact, which can be unidirectional or bidirectional. The dotted arrow represents the hypothetical effect of ADA directly on efficacy without impacting drug exposure. ADA, anti‐drug antibody; NAb, neutralizing antibody